INCYMEDIUM SIGNALFINANCIAL10-K

INCY demonstrated strong cash generation and balance sheet improvement with substantially higher cash reserves and reduced R&D spending while maintaining revenue growth.

The company's cash position improved dramatically to $3.1B, suggesting either successful capital raising, strong operating cash flow, or both, which provides significant financial flexibility for future investments and operations. The 21% reduction in R&D expenses alongside continued revenue growth indicates improved operational efficiency, though investors should monitor whether reduced research spending impacts the company's innovation pipeline long-term.

Comparing 2026-02-10 vs 2025-02-10View on EDGAR →
FINANCIAL ANALYSIS

INCY's financial position strengthened considerably with cash reserves growing substantially to $3.1B and total assets expanding 28% to $7.0B, while stockholders' equity approached $5.2B. Revenue grew a solid 14% to $3.4B, but the company meaningfully reduced R&D expenses by 21% to $2.1B, suggesting either completion of major research programs or strategic reallocation of resources. The overall picture reflects a company generating strong cash flow and optimizing its cost structure while maintaining growth momentum.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+83.5%
$1.7B→$3.1B

Cash position surged 83.5% — strong cash generation or capital raise providing significant financial cushion.

Inventory
Balance Sheet
+71.7%
$58.9M→$101.1M

Inventory surged 71.7% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+55.1%
$3.2B→$5.0B

Current assets grew 55.1% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+49.9%
$3.4B→$5.2B

Equity base grew 49.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+27.8%
$5.4B→$7.0B

Asset base grew 27.8% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-21.4%
$2.6B→$2.1B

R&D spending cut 21.4% — could signal cost discipline or concerning reduction in innovation investment.

Revenue
P&L
+13.7%
$3.0B→$3.4B

Revenue growing 13.7% — solid top-line momentum, watch margins for quality of growth.

SG&A Expense
P&L
+10.8%
$1.2B→$1.4B

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

Total Liabilities
Balance Sheet
-10.3%
$2.0B→$1.8B

Liabilities reduced 10.3% — deleveraging improves balance sheet strength and financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-10
PRIOR — 2025-02-10
ADDED
As of February 3, 2026 there were 199,014,486 shares of Common Stock, $.001 par value per share, outstanding.
or other government proposals regarding drug pricing; the expected impact of recent accounting pronouncements and changes in tax laws; expected losses; the fluctuation of losses; the currency translation impact associated with non-U.S.
Incyte, JAKAFI, MINJUVI, MONJUVI, OPZELURA, PEMAZYRE and ZYNYZ are our registered trademarks and NIKTIMVO and JAKAFI XR are our trademarks.
Risk Factors of this report before deciding whether to invest in our company.
If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity, and we could face increased costs, penalties and a loss of business.
If recent proposals for changes to Medicare and Medicaid reimbursement of drug prices are adopted into law, our results of operations and financial condition could be harmed.
If the use of our products harms or is perceived to harm patients or product liability lawsuits are brought against us, our regulatory approvals could be revoked or negatively impacted and we could face substantial liabilities, which may require us to limit commercialization of our products, and our results of operations could be harmed.
We expect to continue to incur significant expenses to discover and develop drugs, which could result in future losses and impair our ability to achieve sustained profitability in the future.
Increasing use of social media and new technology, including artificial intelligence, could give rise to liability, breaches of data security or reputational damage, which could harm our business and results of operations.
These therapeutic areas are: Hematology, Oncology, and Inflammation and Autoimmunity ( IAI ).
REMOVED
As of February 3, 2025 there were 193,524,350 shares of Common Stock, $.001 par value per share, outstanding.
Incyte, JAKAFI, MINJUVI, MONJUVI, OPZELURA, PEMAZYRE and ZYNYZ are our registered trademarks and NIKTIMVO is our trademark.
of this report, Risk Factors, before deciding whether to invest in our company.
If we fail to comply with applicable laws and regulations, we could lose our approval to market our products or be subject to other governmental enforcement activity.
If the use of our products harms or is perceived to harm patients, our regulatory approvals could be revoked or otherwise negatively impacted or we could be subject to costly product liability claims.
The illegal distribution and sale by third parties of counterfeit or unfit versions of our or our collaborators products or stolen products could harm our business and reputation.
If product liability lawsuits are brought against us, we could face substantial liabilities and may be required to limit commercialization of our products, and our results of operations could be harmed.
We expect to continue to incur significant expenses to discover and develop drugs, which could result in future losses and impair our achievement of and ability to sustain profitability in the future.
Increasing use of social media and new technology could give rise to liability, breaches of data security, or reputational damage, which could harm our business and results of operations.
One therapeutic area is Hematology/Oncology, which comprises Myeloproliferative Neoplasms (MPNs), Graft-Versus-Host Disease (GVHD), solid tumors and hematologic malignancies.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →